%0 Journal Article
%T Combination immunotherapy with interleukin©\2 surface©\modified tumor cell vaccine and programmed death receptor©\1 blockade against renal cell carcinoma
%A Jimin Gao
%A Jinlong Li
%A Shihao Wu
%A Xiaojun Shi
%A Xinji Zhang
%A Zhaolin Long
%A Zhiming Hu
%J Archive of "Cancer Science".
%D 2019
%R 10.1111/cas.13842
%X Immunotherapy may be an effective way to prevent postoperative recurrence of renal cell carcinoma. Streptavidin©\interleukin©\2 (SA©\IL©\2) surface©\modified tumor cell vaccine developed through our protein©\anchor technology could induce specific antitumor T©\cell responses, but this immunotherapy cannot completely eradicate the tumor. These effector T cells highly expressed programmed death receptor©\1 (PD©\1), and the expression of programmed death ligand©\1 (PD©\L1) in the tumor environment also was upregulated after SA©\IL©\2©\modified vaccine therapy. PD©\1/PD©\L1 interaction promotes tumor immune evasion. Adding PD©\1 blockade to SA©\IL©\2©\modified vaccine therapy increased the number of CD4+, CD8+ and CD8+interferon©\¦Ã+ but not CD4+Foxp3+ T cells. PD©\1 blockade could rescue the activity of tumor©\specific T lymphocytes induced by the SA©\IL©\2©\modified vaccine. Combination therapy delayed tumor growth and protected mice against a second Renca cells but not melanoma cells challenge. Taken together, PD©\1 blockade could reverse immune evasion in the treatment with SA©\IL©\2©\modified vaccine, and eventually induce a stronger specific antitumor immune response against renal cell carcinoma
%K immunotherapy
%K interleukin 2
%K programmed death receptor©\1
%K renal cell carcinoma
%K vaccine
%U https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6317916/